ARMFDAVIDAC

ARMFDAVIDAC is a clinical trial treatment arm identifier used in the **AML18** trial (NCT02272478), sponsored by **Cardiff University**. It refers to the third randomization (**Arm F**) within the trial, which compares the efficacy of a third course of standard-dose **daunorubicin** and **cytarabine** (DA) against **intermediate-dose cytarabine** (IDAC) in older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are minimal residual disease (MRD) negative after their first course of induction therapy. The regimen involves the cytotoxic agents daunorubicin, an anthracycline that intercalates DNA and inhibits topoisomerase II, and cytarabine, a pyrimidine analog that inhibits DNA synthesis by interfering with DNA polymerase.

Other names

daunorubicin + cytarabine vs intermediate-dose cytarabineDA vs IDAC